CeramOptec GmbH was established in 1988 as the nucleus of today's biolitec AG. Fast expansion activities in the early years resulted in a branch set up in the USA in 1989, and another branch in Malaysia in 1991.


Consolidation of laser expertise

The introduction of the first diode laser for photodynamic therapy worldwide, today enables clinics to reduce costs - both in terms of procurement and maintenance.


Approvals from the European and US authorities for various other lasers with different wavelengths consolidate our international, leading market position.


Developing competency in photodynamic therapy

biolitec AG, today's parent company of CeramOptec GmbH, was founded in 1999. Activities for conducting research on photodynamic substances were initiated. By acquiring QuantaNova Ltd., biolitec AG was able to immediately market a Europe-wide licensed photosensitizer named Temoporfin - a new therapeutic option for the treatment of head and neck cancer.


In parallel, a new procedure of treating vein problems was introduced. Laser fibers are used to seal varicose veins permanently - in a minimally invasive way. Today, the so-called ELVeS® procedure is the market leader in Europe and the USA.


Enforcement of strategic positioning

Further expansions based on biolitec's entry into the stock market in 2000. New indications and applications are successfully marketed. This includes the therapy of benign prostate hyperplasia (BPH) as well as the treatment of age-related macular degeneration (AMD). New licenses and formulations of Temoporfin are in preparation or are being tested in studies.


Today, biolitec AG is one of the world's leading companies in the field of laser medicine. The uniqueness of its portfolio is based on innovative treatment procedures and photodynamic therapy.



biolitec pharma ltd.